Navigation Links
Neogen's Rapid Test for Salmonella enteritidis Receives FDA Approval

LANSING, Mich., Jan. 12, 2011 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) today announced that its rapid test for Salmonella enteritidis (SE) has been determined by the U.S. Food and Drug Administration (FDA) to be equivalent to the FDA's traditional testing method in accuracy, precision, and sensitivity for detecting SE.

The FDA's determination of equivalency will allow egg producers and processors to use Neogen's Reveal for SE to shorten the testing time and comply with the FDA's recently implemented SE-regulations without further scrutiny. In November, the AOAC International validated the accuracy of the Reveal for SE system when testing either environmental or egg samples.

"The FDA's determination of equivalency further validates our test as an invaluable tool to egg producers, as they comply with the FDA's new regulations, and seek to further reduce the likelihood of SE-contaminated eggs reaching consumers," said Ed Bradley, Neogen's vice president of Food Safety. "Until our introduction of an effective rapid test for SE, the industry had to wait up to 7 days for an outside laboratory's test results. Reveal for SE enables the industry to get quicker results — and provides the accurate answer they need to manage their flocks and egg production."

Neogen, in cooperation with USDA scientists, began the development of this test in 2000.

"Using a rapid test for SE that uses the same sample enrichment protocol as the FDA not only allows analysts to quickly screen out negative test results, but also is compatible with the FDA confirmation process by using the same enriched samples," said Bradley. "Especially now, with the heightened concern for contaminated eggs, time is of the essence."

The foodborne illness caused by SE is generally due to eating raw, incompletely cooked, or recontaminated eggs. Ingestion of SE-contaminated poultry meat is the second leading cause of this illness.

Neogen's comprehensive line of products it offers to the poultry industry also includes a full line of agricultural cleaners and disinfectants, and rodenticides, to stop the spread of infectious disease from animal to animal, and from production facilities to the consumer.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases, and sanitation concerns, and dehydrated culture media. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
2. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
3. Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Rapid Increase in the Number of Worldwide Nanotechnology Degree Programs
6. Celsis Rapid Detections Updated Drug Master Files (DMFs) Accepted by FDA
7. An optical traffic cop for rapid communication
8. Maine Medical Center Chooses Business Intelligence Solution from Rapid Insight Inc.
9. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
10. Wound Management Technologies, Inc. Rapidly Expands Its International Presence
11. Study: Era of Rapid Growth in Biomedical Research Over
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):